GSK plc Deferred Tax Expense Income
GSK plc (GLAXF) reported Deferred Tax Expense Income of -GBP 283.00 million for the 12-month period ending 2025-12-31, per its 20-F filed 2026-03-06.
Financial Statements › Expense Statement › Operating Expenses
ifrs-full:DeferredTaxExpenseIncome · last filed 2026-03-06
| Period end | Deferred Tax Expense Income 12 month | Deferred Tax Expense Income 12 month as first filed |
|---|---|---|
| 2025-12-31 | -283.00M GBP 20-F · filed 2026-03-06 | |
| 2024-12-31 | -1.03B GBP 20-F · filed 2026-03-06 | |
| 2023-12-31 | -865.00M GBP 20-F · filed 2026-03-06 | |
| 2022-12-31 | -784.00M GBP 20-F · filed 2025-03-03 | |
| 2021-12-31 | -848.00M GBP 20-F · filed 2024-03-05 | -1.00B GBP 20-F · filed 2022-03-08 |
| 2020-12-31 | -644.00M GBP 20-F · filed 2023-03-10 | -693.00M GBP 20-F · filed 2021-03-12 |
| 2019-12-31 | -183.00M GBP 20-F · filed 2022-03-08 | |
| 2018-12-31 | -414.00M GBP 20-F · filed 2021-03-12 | |
| 2017-12-31 | -263.00M GBP 20-F · filed 2020-03-06 | |
| 2016-12-31 | -541.00M GBP 20-F · filed 2019-03-15 | |
| 2015-12-31 | -418.00M GBP 20-F/A · filed 2018-03-20 |